Medical Oncology and Tumor Pharmacotherapy

, Volume 8, Issue 4, pp 229–233 | Cite as

Iron, free radicals and cancer

  • Peter Reizenstein


Free radicals, intermediates in the tissue damage caused by radiation, are formed,inter alia, in interactions catalyzed by iron, which synergizes with radiation and some cytostatics (anthracyclins) in causing cell damage. Conversely, iron chelators can counteract cell damage. Similarly, antioxidants can slow atherogenesis, caused in part by oxidative stress and free radicals. Cell damage is also prevented by physiological defense systems like Superoxide dismutase, against endogenous free radicals formed by granulocytes, monocytes, etc. Iron can thus induce free radicals which cause DNA double strand breaks and oncogene activation. This is suggested by four epidemiological studies suggesting a higher cancer risk in patients with larger iron stores than in those with small iron stores. In addition to its effect on carcinogenesis, iron can also maintain the growth of malignant cells as well as growth of pathogens. Breast cancer cells, for instance, display 5-15 times more transferrin receptors than normal breast tissue. Iron-carrying transferrin is in fact a growth factor. Hyposideremia in patients with cancer or infection is not a paraphenomenon but a functioning defense mechanism (’nutritional immunity’). If this immunity is broken by iron administration, relapses of diseases like tuberculosis, brucellosis, and malaria have been described. While iron-deficiency anemia should of course be diagnosed, treated and if possible prevented, there are good reasons to avoid over-utilization of medicamental iron.

Key words

Iron Free radicals Cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stevens R, Richard G, Kalkwarf D R: Iron, radiation and cancer.Envir Hlth Perspect 87, 291–300 (1990).CrossRefGoogle Scholar
  2. 2.
    Kizaki M, Krmakar A, Lin C W, Koeffler H P: Regulation of Superoxide dismutase mRNA in hematopoietic cells and its relation to cytotoxicity by tumor necrosis factor.Int Soc Hematol 1149, 290a (1990) (abstract).Google Scholar
  3. 3.
    Kushner B H, Cheung N K V: Relative oxygen species (ROS) do not play a major role in the lysis of human tumor cells by “human neutrophils (PMN) armed with cytophilic monoclonal antibody (MoAB).Int Soc Hemat abstract 541, p. 188a (1990).Google Scholar
  4. 4.
    Knight R D, Perry J J, Hargis J B, Wright D G: The use of oral mucosal neutrophil counts to follow the development and resolution of neutropenia in patients given high dose, myelosuppressive chemotherapy.Int Soc Hemat abstract 737, p. 187a (1990); Shies,idem, abstract 652, p. 165a.Google Scholar
  5. 5.
    Leanderson P, Seger A, Tagesson C H: A new method to determine hydroxyl radicals after the activation of human granulocytes.Swed Phys natn Conf., abstract 10P, p.188 (1990) (in Swedish).Google Scholar
  6. 6.
    Cazzola M, Bergamaschi G, Dezza L, Arosio P: Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects.Blood 75, 1903–1919 (1990).PubMedGoogle Scholar
  7. 7.
    Weinberg E D: Cellular iron metabolism in health and disease.Drug Metab Rev 22, 531–579 (1990).CrossRefPubMedGoogle Scholar
  8. 8.
    Steinbrecher U P, Parthasarathy S, Leake D S, Witztum J L, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids.Proc natn Acad Sci USA 81, 3883–3887 (1989).CrossRefGoogle Scholar
  9. 9.
    Riemersma R A, Wood D A, Macintyre CCA, Elton R A, Gey K F, Oliver M F: Risk of angina pectoris and plasma concentrations of vitamins A, C, E and carotene.Lancet 337, 1–5 (1991).CrossRefPubMedGoogle Scholar
  10. 10.
    Ahmadzadeh N, Shingu M, Nobunaga M: Iron-binding proteins and free iron in synovial fluids of rheumatoid arthritis patients.Clin Rheumat 8, 345- 351 (1989).CrossRefGoogle Scholar
  11. 11.
    Lantz B, Adolfsson J, Lagerlöf B, Reizenstein P: Cardiomyopathy in leukemia with reference to rubidomycin cardiotoxicity.Cancer Chemother Pharmac 2, 95–99 (1979).Google Scholar
  12. 12.
    Luoma P V, Stengard J, Korpela Het ai: Lipid peroxides, glutathione peroxidase, high density lipoprotein subfractions and apolipoproteins in young adults.J int Med 227, 287–289 (1990).Google Scholar
  13. 13.
    Pallab K Ganguly: Antioxidant therapy in congestive heart failure: is there any advantage?J int Med 229. 205–208 (1991).Google Scholar
  14. 14.
    Muta K, Nishimura J, Abe Y, Nawata H: Mechanism of decrease in transferrin receptor synthesis by interferon-treated human lymphoblastoid cells.Leukemia Lymphoma 2, 427–432 (1990).CrossRefGoogle Scholar
  15. 15.
    Hershko C, Theanacho E N, Spira D T, Peter H H, Dobbin P, Hider R C: Malaria control by iron deprivation: the 3-hydroxypyridin-4-one iron chelators.Int Soc Hemat abstract 129, p. 35a (1990).Google Scholar
  16. 16.
    de Sousa M, Potaznik D: Proteins of the metabolism of iron cells of the immune system and malignancy, in Prasad N (ed):Vitamins, Nutrition, and Cancer, 231–239. Basle, Karger (1984).Google Scholar
  17. 17.
    Fargion S, Fracanzani A L, Brando B, Arosio P, Levi S, Coppelini M D, Fiorelli G: H-ferritin receptor: its role in the control of cell growth.Int Soc Hemat abstract 356, p. 91a (1990).Google Scholar
  18. 18.
    Potaznik D, Groshen S, Miller D, Bagin R, Bhalla R, Schwartz M, de Sousa M: Association of serum iron, serum transferrin saturation and serum ferritin with survival in acute lymphocytic leukemia.Am J Ped Hemat 9, 350–355 (1987).CrossRefGoogle Scholar
  19. 19.
    Reizenstein P: The biological response to disease, inHematologic Stress-syndrome. New York, Praeger (1983).Google Scholar
  20. 20.
    Ogier C, Giannoulis N, Jacobs A, Reizenstein P: The use of serum ferritin to identify good and bad prognosis groups in acute myeloid leukemia.Haematologica 69, 111–112 (1984).PubMedGoogle Scholar
  21. 21.
    Salim A. S.: Oxygen-derived free radicals and the prevention of duodenal ulcer.Am J med Sci 300, 1–6 (1990).CrossRefPubMedGoogle Scholar
  22. 22.
    Merk K, Mattsson B, Mattsson A, Holm G, Gullbring B, Björkholm M: The incidence of cancer among blood donors.Int J Epidem 19, 505–509 (1991).CrossRefGoogle Scholar
  23. 23.
    Lieder G: Iron state in regular blood donors.Scand J Haemat 11, 342–349 (1973).Google Scholar
  24. 24.
    Höglund S, Reizenstein P: Studies in iron absorption, IV. Effect of humoral factors on iron absorption.Blood 34, 488–495 (1969).PubMedGoogle Scholar
  25. 25.
    Westin S I: How much iron does food contain, and how much is fortification?Näringsforskning 19, 14–16 (1975) (in Swedish).Google Scholar
  26. 26.
    Reizenstein P: Läkemedlens plats vis förebyggande och behandling av järnbrist.Sv Farm Tidskr 81, 385- 390 (1977).Google Scholar
  27. 27.
    Report from the National Swedish Expert group for nutrition.Vår föda 42, 63 (1990) (in Swedish).Google Scholar
  28. 28.
    Holmgren G : A forgotten health problem — menorrhagia. Kabijourn No. 4, p. 18 (1990)(in Swedish).Google Scholar
  29. 29.
    Pollit E, Haas J, Levitsky D A: International Conference on Iron Deficiency and Behavioural Development.Am J Clin Nutr 50, 565 (1989).Google Scholar
  30. 30.
    Dalhöj J, Wiggers P : Screening for idiopathic hemochromatosis — performance of screening tests. XXth International Congress of Internal Medicine, Stockholm 1990, abstract 53, p. 14.Google Scholar
  31. 31.
    Reizenstein P, Höglund S, Landegren J, Carlmark B, Forsberg K: Iron metabolism in porphyria cutanea tarda.Acta Med Scand 198, 95–99 (1975).PubMedGoogle Scholar
  32. 32.
    Situnayake R D, Crump B J, Turnham D I: Lipid peroxidation and hepatic antioxidants in alcoholic liver disease.Gut 31, 1311–1317 (1990),CrossRefPubMedGoogle Scholar
  33. 33.
    Togashi H, Shinzawa H, Wakabayashi H: Activities of free oxygen radical scavenger enzymes in human liver. I.Hepatology 11, 200–205 (1990).CrossRefGoogle Scholar
  34. 34.
    Staehr-Johansen K : 3.5.1. Study on appropriate utilization of iron during pregnancy, in Qual Care Newsletter, p. 12. Copenhagen, WHO (1990).Google Scholar
  35. 35.
    Reizenstein P: Free supply of iron supplementation in chronic iron deficiency. Editorial.Nordisk Med 74, 1114–1115 (1965) (in Swedish).Google Scholar
  36. 36.
    Reizenstein P: Side effects of increased iron intake.Näringsforskning 19, 17–21 (1975) (in Swedish).Google Scholar
  37. 37.
    Reizenstein P, Ljunggren G, Smedby B, Agenäs I, Penchansky M: Overprescribing iron tablets to elderly people in Sweden.Br Med J ii, 962–963 (1979).CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1991

Authors and Affiliations

  • Peter Reizenstein
    • 1
  1. 1.Hematology LaboratoryKarolinska HospitalStockholmSweden

Personalised recommendations